Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2011 Jun;32(11):1345-61. doi: 10.1093/eurheartj/ehr112. Epub 2011 Apr 29. Review.

2.

'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.

Jacobson TA.

Int J Clin Pract. 2011 Jan;65(1):82-101. doi: 10.1111/j.1742-1241.2010.02547.x. Epub 2010 Nov 24. Review.

PMID:
21105969
3.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
4.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
5.

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

Ito MK.

Atherosclerosis. 2015 Oct;242(2):647-56. doi: 10.1016/j.atherosclerosis.2015.06.012. Epub 2015 Jun 11. Review.

PMID:
26296750
6.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
7.

TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.

Handelsman Y, Shapiro MD.

Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7. Review.

PMID:
27819772
8.

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.

Sharma RK, Singh VN, Reddy HK.

Vasc Health Risk Manag. 2009;5:793-9. Epub 2009 Sep 24. Review.

9.
10.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
11.

[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].

Bajnok L.

Orv Hetil. 2014 Jan 12;155(2):62-8. doi: 10.1556/OH.2014.29797. Review. Hungarian.

PMID:
24389322
12.

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Chapman MJ, Le Goff W, Guerin M, Kontush A.

Eur Heart J. 2010 Jan;31(2):149-64. doi: 10.1093/eurheartj/ehp399. Epub 2009 Oct 12. Review.

13.

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

Toth PP, Barylski M, Nikolic D, Rizzo M, Montalto G, Banach M.

Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):353-68. doi: 10.1016/j.beem.2013.11.002. Epub 2013 Nov 15. Review.

PMID:
24840264
14.

The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.

Windler E, Schöffauer M, Zyriax BC.

Diab Vasc Dis Res. 2007 Jun;4(2):136-42. Review.

PMID:
17654448
15.

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.

Toth PP.

Vasc Health Risk Manag. 2016 May 6;12:171-83. doi: 10.2147/VHRM.S104369. eCollection 2016. Review.

16.

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Matikainen N, Taskinen MR.

Curr Cardiol Rep. 2012 Dec;14(6):721-31. doi: 10.1007/s11886-012-0309-3. Review.

PMID:
22941588
18.

Fibrates and niacin: is there a place for them in clinical practice?

Wierzbicki AS, Viljoen A.

Expert Opin Pharmacother. 2014 Dec;15(18):2673-80. doi: 10.1517/14656566.2014.972365. Epub 2014 Oct 16. Review.

PMID:
25318657
19.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Postgrad Med J. 2008 Nov;84(997):590-8. doi: 10.1136/hrt.2007.125401. Review.

PMID:
19103817
20.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280

Supplemental Content

Support Center